Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
2.500
-0.270 (-9.75%)
At close: Sep 8, 2026, 4:00 PM EDT
2.480
-0.290 (-10.47%)
Pre-market: Sep 9, 2026, 4:54 AM EDT
Valion Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
52
Market Cap
2.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 27.82M |
| Curis | 4.31M |
| SciSparc | 856.00K |
| Jupiter Neurosciences | 64.69K |
| Virax Biolabs Group | 12.42K |
VBIO News
- 7 days ago - Valion Bio appoints CFO Lisa Wolf as president, COO - TheFly
- 7 days ago - Valion Bio Announces Changes to Management and Board of Directors - Accesswire
- 11 days ago - Valion Bio Inc trading halted, news pending - TheFly
- 12 days ago - Valion Bio announces 1-for-25 reverse stock split - TheFly
- 12 days ago - Valion Bio Announces Reverse Stock Split - Accesswire
- 23 days ago - Valion Bio announces U.S. government-funded entolimod studies - TheFly
- 23 days ago - Valion Bio says Ukraine Ministry of Health accepts entolimod regulatory dossier - TheFly
- 25 days ago - Valion Bio Quarterly report: Q2 2026 - Filings